Buprenorphine: Clinical tips for prescribing for chronic pain and/or Opioid Use Disorder (Recorded Session)

Friday, November 15, 2024, 12:00 AM - Sunday, November 14, 2027, 11:59 PM


AMA PRA Category 1 Credits™ (1.00 hours), ACPE Contact Hour(s) (1.00 hours), ANCC Contact Hours (1.00 hours), Non-Physician Attendance (1.00 hours)

Recorded Session

Buprenorphine is a safe and effective medication for treatment of both opioid use disorder and chronic pain. We will consider its history, FDA - approved products, and some principles for clinical use.  

Mark Murphy, MD, is a clinical assistant professor at the University of Washington Department of Family Medicine and board-certified in addiction medicine. He received his medical degree from Creighton University School of Medicine and has been in practice for more than 20 years, currently practicing with MultiCare in his area of expertise, Pain Management/Addiction Medicine. Dr. Mark T. Murphy has extensive experience in treating rheumatoid arthritis, anxiety disorders, depression, among other conditions. 

--

This is a series of livestreamed webinars and on-demand online courses to meet the need for current pain management education that focuses on integrative evidence-based approaches and risk reduction for person-centered care. Both pharmacologic and non-pharmacologic approaches will be highlighted with experts representing a variety of health and therapeutic professions.

1. Describe the clinical pharmacology of buprenorphine.
2. Discuss the safety and efficacy of buprenorphine when used to treat pain and co-occurring substance use disorder.
3. Summarize the products and formulations of buprenorphine that are available in the United States.
4. Understand clinical scenarios that represent common presentations with recommendations for medication management.

1. Describe the clinical pharmacology of buprenorphine.
2. Discuss the safety and efficacy of buprenorphine when used to treat pain and co-occurring substance use disorder.
3. Summarize the products and formulations of buprenorphine that are available in the United States.
4. Understand clinical scenarios that represent common presentations with recommendations for medication management

1. Describe the clinical pharmacology of buprenorphine.
2. Discuss the safety and efficacy of buprenorphine when used to treat pain and co-occurring substance use disorder.
3. Summarize the products and formulations of buprenorphine that are available in the United States.
4. Understand clinical scenarios that represent common presentations with recommendations for medication management.

This activity has been planned and implemented in accordance with the accreditation requirements of the Accreditation Council for Continuing Medical Education (ACCME) Medicine. The Elson S. Floyd College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

Elson S. Floyd College of Medicine designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity meets the criteria for up to 1.00 hours of Category I CME credit to satisfy the re-licensure requirements of the Washington State Medical Quality Assurance Commission.

 

The Washington State University College of Pharmacy and Pharmaceutical Sciences is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

 

Accessibility

WSU College of Medicine Continuing Medical Education (CME) is committed to ensuring that its programs, services, goods and facilities are accessible to individuals with disabilities as specified under Section 504 of the Rehabilitation Act of 1973 and the Americans with Disabilities Act of 2008. If you have needs that require accommodation please contact the CME Unit at [email protected]

WSU Notice of Nondiscrimination

Please visit the Office of Compliance and Civil Rights to view Washington State University's policies.

WSU Institutional Neutrality

At Washington State University, we are committed to fostering an environment where diverse ideas and perspectives can flourish. As such, the university will maintain a practice of neutrality and will not take a position on contentious political or social issues, except in rare circumstances. Please visit WSU's Office of the President for more information.

Disclaimer

The material presented in this continuing medical education program is being made available for educational purposes only. This material is not intended to represent the best or only methods or procedures appropriate for the medical situation discussed; rather the material is intended to present an approach, view, statement, or opinion of the authors or presenters, which may be helpful or of interest to other practitioners. This program does not represent or speak on behalf of Washington State University and/ or Elson S. Floyd College of Medicine. Participants should carefully consider all available scientific data before acting on knowledge gained through this activity.

Mitigation of Relevant Financial Relationships

Washington State University Elson S. Floyd College of Medicine adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.